Nektar Therapeutics Insider Activity: Jonathan Zalevsky Sells Shares

Nektar Therapeutics (NASDAQ:NKTR) recently saw an insider transaction involving Jonathan Zalevsky, who sold 10,300 shares of the company's stock. This transaction took place on February 19th, with the shares sold at an average price of $1.01 each, amounting to a total sale value of $10,403. Following this sale, Zalevsky retains ownership of 316,604 shares, valued at approximately $319,770.04. This transaction indicates a decrease of 3.15% in his overall position in the company.

The details of this transaction were made public in a legal filing with the SEC, ensuring transparency in insider trading activities.

Certainly, it is essential to keep track of insider trading as it can sometimes give clues about a company's future performance.

In a related note, Jonathan Zalevsky recently made another significant trade. On December 19th, he sold 51,115 shares of Nektar Therapeutics at an average price of $0.94, bringing the total value of that sale to $48,048.10.

Nektar Therapeutics Stock Performance Insights

As for the stock's performance, shares of NKTR experienced a slight decline of $0.02 during midday trading, bringing the price down to $0.93. The trading volume for that day stood at 1,217,794 shares, which is lower than the average trading volume of 2,430,165 shares. The company's 50-day simple moving average currently rests at $0.92, while the 200-day simple moving average is at $1.12. Nektar Therapeutics holds a market capitalization of $171.95 million, a P/E ratio of -1.11, and a beta of 0.58. Additionally, the stock has seen a 52-week range with a low of $0.63 and a high of $1.93.

Analyst Perspectives on Nektar Therapeutics

A number of analysts have recently provided their evaluations of Nektar Therapeutics. For instance, Piper Sandler began covering the company on November 4th, assigning an "overweight" rating and setting a price target of $7.00. Meanwhile, HC Wainwright reaffirmed a "buy" rating with a target price of $6.50 in a report published on January 13th. Additionally, B. Riley initiated coverage on January 8th, giving Nektar Therapeutics a "buy" rating and a price target of $4.00. Currently, the consensus rating from analysts is classified as a "Moderate Buy," with an average price target set at $4.08.

It is notable that six research analysts have provided their ratings, with two recommending a hold, four recommending a buy, and one giving a strong buy rating.

Institutional Investors and Hedge Fund Activities

Recently, several hedge funds and institutional investors have adjusted their stakes in Nektar Therapeutics. For example, Two Sigma Securities LLC increased its position by 56.3% in the fourth quarter, now holding 27,654 shares, valued at approximately $26,000. Other notable transactions include Harvest Investment Services LLC, US Asset Management LLC, Valence8 US LP, and Intech Investment Management LLC, each purchasing new positions in the company's stock. Overall, institutional investors hold about 75.88% of Nektar Therapeutics' shares.

About Nektar Therapeutics

Founded as a biopharmaceutical company, Nektar Therapeutics focuses on the discovery and development of innovative medicines primarily in the field of immunotherapy. The company is currently advancing its portfolio, notably the drug rezpegaldesleukin, a cytokine Treg stimulant undergoing phase 2 clinical trials for systemic lupus erythematosus and ulcerative colitis. Additionally, it is in phase 2b trials for atopic dermatitis and psoriasis. Another promising candidate is NKTR-255, an IL-15 receptor agonist currently in phase 1 trials, aimed at enhancing the immune system's ability to combat cancer.

Nektar, Therapeutics, Insider